What did @itslittlelachy actually say?
He called Australia's PBS (Pharmaceutical Benefits Scheme) system for TRT "absolutely just dog shit" and flagged a specific line from what appears to be official PBS or prescribing documentation. The quoted text suggests that withdrawing TRT would only cause symptoms "not expected to have serious consequences." His core argument: the PBS system's eligibility rules and regulations are too rigid and actively harm men with low testosterone.
He didn't manufacture a claim out of thin air. He's pointing to real documentation and real frustration that a lot of men on Australian TRT forums and Facebook groups have been voicing for years. Whether his anger is fully justified is a different question, but the frustration has a legitimate basis.
Does the science back this up?
Partially, yes. The claim that testosterone withdrawal causes symptoms "without serious consequences" is genuinely contested in the medical literature. That framing is outdated and too dismissive.
Research published by Bhasin et al. (2010, New England Journal of Medicine) established that hypogonadism, when left untreated, is associated with reduced bone mineral density, metabolic dysfunction, and impaired quality of life. More recently, Corona et al. (2017, Sexual Medicine Reviews) found that untreated hypogonadism carries measurable cardiovascular and metabolic risk over time. Calling withdrawal symptoms clinically insignificant contradicts this body of evidence.
The PBS eligibility criteria for testosterone in Australia require a confirmed diagnosis of pathological hypogonadism, typically defined by two fasting morning total testosterone readings below 8 nmol/L, with documented symptoms. This threshold excludes a significant number of men who fall in what clinicians call the "gray zone" (8-12 nmol/L) and who may still experience symptomatic benefit from treatment. The Endocrine Society's 2018 clinical practice guidelines, authored by Bhasin et al., acknowledge this ambiguity directly.
What did they get wrong (or right)?
He got the broad strokes right. The PBS system does impose strict thresholds, and its documentation language around withdrawal consequences is clinically questionable. Credit where it's due.
What he gets wrong, or at least oversimplifies, is framing this purely as the system being "ridiculous." Regulatory caution around testosterone exists for documented reasons. Long-term testosterone therapy carries real risks, including erythrocytosis (elevated red blood cell count), potential effects on cardiovascular outcomes, and suppression of natural hormone production. The TRT-MACE trial data published by Lincoff et al. (2023, New England Journal of Medicine) did show testosterone therapy was non-inferior to placebo for major cardiovascular events in men with hypogonadism, which is genuinely reassuring, but it also reinforces why structured monitoring matters.
Regulatory conservatism isn't always malice or incompetence. Sometimes it's a response to decades of overprescribing and product marketing that outpaced the evidence. The PBS system is blunt and imperfect, but it isn't arbitrary.
- The PBS threshold of 8 nmol/L is lower than guidelines used in the US and UK, where 10.4-12 nmol/L is more commonly referenced.
- Symptom-based criteria are underweighted in Australian PBS rules compared to international practice.
- The documentation language he quoted does appear inconsistent with current evidence on hypogonadism outcomes.
What should you actually know?
If you're a man in Australia investigating TRT, understanding what you're actually dealing with matters more than being angry at a system.
First, PBS-subsidised testosterone is not your only path. Private prescriptions are legal and available, though more expensive. Telehealth platforms operating under Australian Health Practitioner Regulation Agency (AHPRA) guidelines can assess and prescribe appropriately for men who don't meet PBS thresholds but have genuine clinical need.
Second, "low testosterone" isn't one thing. Total testosterone, free testosterone, sex hormone-binding globulin (SHBG), and symptom burden all need to be interpreted together. A single number doesn't tell the full story, and neither does a TikTok video.
Third, the quote he flagged, about withdrawal not causing serious consequences, likely refers to PBS justification language around step-therapy or treatment gaps, not a clinical claim about your individual health. That context matters, even if the language is poorly worded.
If you suspect hypogonadism, the right step is a full hormonal panel reviewed by a doctor experienced in men's health endocrinology, not a PBS printout and a TikTok comment section.